The company held the first half of the board of directors, the board of supervisors half-year performance hit a record high
Release time:
2020-07-31
News from our newspaper 8# April 29 , the group company held the 11 meeting of the 10th board of directors of the company by means of communication, and reviewed and approved the "Jianfeng group 2019 semi-annual report", "on the company's internal control system amendment" and other proposals. In the first half of
, the company focused on the general working policy of "innovation and reform, integration and promotion, scientific layout and steady development " , grasped the opportunities brought by economic structure optimization and industrial upgrading, continuously integrated resources internally, improved the internal management system and improved the operation efficiency of enterprises. In the first half of 2019 , the company realized total operating income of 16.86 .2 billion yuan, up 12.17% year-on-year, net profit attributable to owners of the parent company 4.76 .6 billion yuan, up 57.55% year-on-year, and the semi-annual operating performance reached another record high. As of the end of 2019 6 , the company's total assets were 53.83 .4 billion yuan, up 9.82 from the beginning of the year ; Net assets were 38.17 .8 billion yuan, up 10.64 from the beginning of the year. In the first half of the year, the company made a new breakthrough in the expansion of cement business. The group company completed the acquisition of 100%
4500 tons of cement clinker (with waste heat power generation); Yunnan Jianfeng invested ,500 yuan to participate in the establishment of Yunnan Jianfeng Da Zhan Cement Co., Ltd, the company plans to build a cement clinker production line in Mengla County, Xishuangbanna Dai Autonomous Prefecture in accordance with relevant national policies. The company's cement subsidiaries continue to carry out in-depth "three down three improve " activities, steadily implement standardized management, while strictly controlling production costs, and continuously improve labor productivity. Daye Peak, in accordance with the spirit of the Group's standardization year, has implemented standardization of production site management and has achieved good results. Comprehensive treatment of cement packaging dust, hydraulic system of limestone stacker, cement cooling commissioning and other technical renovation projects have been carried out in an orderly manner, all of which have reached good expectations. Yunnan Jianfeng timely grasps the price changes of related products of upstream suppliers through various channels, and strictly controls the procurement cost of raw materials. Concentrate on the development of market share in the core region as a key work, constantly explore and formulate sales strategies suitable for the regional market, effectively improve the market popularity and share of Jianfeng Cement, and achieve the best business performance since it was put into production. Jianfeng Pharmaceutical continued to increase investment in drug research and development and obtained the Drug Registration Approval for Olopatadine Hydrochloride Eye Drops. In the face of changes in the pharmaceutical sales environment, Spike Pharmaceuticals has integrated its pharmaceutical business and pharmaceutical retail, and strived to extend and expand its third-end market share. Accelerate the consistency evaluation of related drugs, and lay a good foundation for the next step to participate in the centralized procurement of drugs. Jianfeng Pharmaceutical and its subsidiaries continue to increase investment in safety and environmental protection, improve and upgrade various safeguards, and improve the level of automatic control of equipment and facilities; adhere to prevention, improve safety management and three waste treatment capabilities, and effectively reduce environmental protection and safety Production risk. In the first half of the year, Jianfeng Pharmaceutical and its subsidiaries made new progress in a number of technological innovations and engineering construction. Jianfeng Pharmaceutical's internationalization project of annual production of 20
RTO ) and sewage treatment have been put into operation, and the annual output of 1500 tons of acetamiprid powder in pesticide preparation workshop has entered the trial production stage. The renovation of the GMP laboratory of Anhui Zhongwang Small Molecule Targeted Drug Research Institute has been basically completed, and the second phase of the technical renovation project of GMP workshop, including common drugs and small molecule targeted antitumor drugs, which has obtained government approval. The production and operation activities of other business segments of the company are carried out in a standardized and orderly manner.
meeting of the 9th Supervisory Committee and reviewed and approved the relevant report. (Yu
fruit)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page